Sean M. Post, Ph.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Post
Sean Post, M.D., is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Dr. Post received his Ph.D. in Molecular Medicine from the University of Texas Health Science Center at San Antonio in 2003. Dr. Post trained as a postdoctoral fellow in Department of Genetics at the MD Anderson Cancer Center under the tutelage of Dr. Gigi Lozano. In 2011, Dr. Post was appointed as a Tenure-Track faculty member in the Department of Leukemia. Dr. Post’s research is focused on identifying and understanding how novel genetic alterations impact cancer progression. His laboratory’s long-term objectives are develop personalized treatment strategies for patients with hematologic malignancies.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Genetics, Division of Basic Science Research, MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2003 | University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, PHD, Molecular Medicine |
| 1996 | University of Arkansas at Little Rock, Little Rock, AR, USA, BS, Biology |
Postgraduate Training
| 2004-2009 | Postgraduate Training, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2003-2004 | Postgraduate Training, Baylor College of Medicine, Houston, TX |
Experience & Service
Academic Appointments
Member of Faculty, MD Anderson Cancer Center, Houston, TX, 2011 - Present
Military or Other Governmental Service
Sergeant, United States Army, 1989 - 1997
Honors & Awards
| 2011 | MD Anderson Leukemia SPORE Career Development Award, The University of Texas MD Anderson Cancer Center |
| 2010 | 13th International p53 Workshop Outstanding Poster Award and Travel Award |
| 2009 | Genes and Development Program Retreat Award |
| 2009 | 5th International Mdm2 Workshop Outstanding Poster Award |
| 2006 | Ruth Kristensen NIH Postdoctoral Fellowship |
| 2005 | Dodie P. Hawn Fellowship in Cancer Genetics, The University of Texas MD Anderson Cancer Center |
| 2002 | Predoctoral Fellowship, Department of Defense |
| 2001 | 11th Annual Symposia on Cancer Research in San Antonio, Best Student Presentation, San Antonio Cancer Institute |
| 2001 | Department of Molecular Medicine/Institute Biotechnology Annual Retreat, Best Student Presentation, Institute Biotechnology |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Malaney P, Benitez O, Zhang X, Post SM. Assessing the role of intrinsic disorder in RNA-binding protein function: hnRNP K as a case study. Methods 208:59-65, 2022. e-Pub 2022. PMID: 36334888.
- Aitken MJL, Malaney P, Zhang X, Herbrich SM, Chan L, Benitez O, Rodriguez AG, Ma H, Jacamo R, Duan R, Link TM, Kornblau SM, Kanagal-Shamanna R, Bueso-Ramos CE, Post SM. Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing. NAR Cancer 4(4):zcac039, 2022. e-Pub 2022. PMID: 36518526.
- Post SM, Ma H, Malaney P, Zhang X, Aitken MJL, Mak PY, Ruvolo VR, Yasuhiro T, Kozaki R, Chan LE, Ostermann LB, Konopleva M, Carter BZ, DiNardo C, Andreeff MD, Khoury JD, Ruvolo PP. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica 107(6):1311-1322, 2022. e-Pub 2022. PMID: 34732043.
- Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Post SM, Andreeff M. LGALS1 acts as a pro-survival molecule in AML. Biochim Biophys Acta Mol Cell Res 1867(10):118785, 2020. e-Pub 2020. PMID: 32590026.
- Gallardo M, Malaney P, Aitken MJL, Zhang X, Link TM, Shah V, Alybayev S, Wu MH, Pageon LR, Ma H, Jacamo R, Yu L, Xu-Monette ZY, Steinman H, Lee HJ, Sarbassov D, Rapado I, Barton MC, Martinez-Lopez J, Bueso-Ramos C, Young KH, Post SM. Uncovering the role of hnRNP K, an RNA-binding protein, in B-cell lymphomas. J Natl Cancer Inst 112(1):95-106, 2020. e-Pub 2019. PMID: 31077320.
- Hoff FW, Hu CW, Qutub AA, Qiu Y, Hornbaker MJ, Bueso-Ramos C, Abbas HA, Post SM, de Bont ESJM, Kornblau SM. Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse. Proteomics Clin Appl 13(4):e1800133, 2019. e-Pub 2019. PMID: 30650251.
- Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma 60(1):1-12, 2019. e-Pub 2018. PMID: 29741984.
- Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865(7):959-969, 2018. e-Pub 2018. PMID: 29655803.
- Ortiz GJ, Li Y, Post SM, Pant V, Xiong S, Larsson CA, El-Naggar AK, Johnson DG, Lozano G. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene 37(3):332-340, 2018. e-Pub 2017. PMID: 28925402.
- Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury JD, Cortes J, Andreeff M, Post SM. Anexelekto /MER Tyrosine Kinase inhibitor ONO-7475 growth arrests and kills FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Mutant Acute Myeloid Leukemia cells by diverse mechanisms. Haematologica 102(12):2048-2057, 2017. e-Pub 2017. PMID: 28912176.
- Post SM, Kornblau SM, Quintás-Cardama A. p53 pathway dysfunction in AML: beyond TP53 mutations. Oncotarget 8(65):108288-108289, 2017. e-Pub 2017. PMID: 29312530.
- Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver N, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M. Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget 8(43):74378-74390, 2017. e-Pub 2017. PMID: 29088794.
- Quintás-Cardama A, Hu C, Qutub A, Qiu YH, Zhang X, Post SM, Zhang N, Coombes K, Kornblau SM. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia 31(6):1296-1305, 2017. e-Pub 2016. PMID: 27885271.
- Elias H, Galata C, Warschkow R, Schmied BM, Steffen T, Post SM, Marti L. Survival after resection of appendiceal carcinoma by hemicolectomy and less radical than hemicolectomy: A population-based propensity score matched analysis. Colorectal Dis. e-Pub 2017. PMID: 28556480.
- Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov Z. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med 213(9):1723-40, 2016. e-Pub 2016. PMID: 27481130.
- Gallardo M, Hornbaker MJ, Zhang X, Hu P, Bueso-Ramos C, Post SM. Aberrant hnRNP K expression: All roads lead to cancer. Cell Cycle 15(12):1552-7, 2016. PMID: 27049467.
- Lee HJ, Gallardo M, Ma H, Zhang X, Larsson CA, Mejia A, Hornbaker MJ, Qi Y, Su X, Pageon LR, Quintas-Cardama A, Post SM. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL. Blood Cancer J 10(6):434, 2016. e-Pub 2016. PMID: 27284738.
- Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. Cancer Cell 28(4):486-99, 2015. e-Pub 2015. PMID: 26412324.
- Zhang X, Pageon L, Post SM. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer. Oncogene 34(33):4412-20, 2015. e-Pub 2014. PMID: 25435368.
- Quintás-Cardama A, Zhang N, Qiu YH, Post S, Creighton CJ, Cortes J, Coombes KR, Kornblau SM. Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(2):115-127.e15, 2015. e-Pub 2014. PMID: 25248926.
- Jiang S, Minter LC, Stratton SA, Yang P, Abbas HA, Akdemir ZC, Pant V, Post S, Gagea M, Lee RG, Lozano G, Barton MC. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol 62(2):371-9, 2015. e-Pub 2014. PMID: 25281858.
- Chen J, Shin JH, Zhao R, Phan L, Wang H, Xue Y, Post SM, Ho Choi H, Chen JS, Wang E, Zhou Z, Tseng C, Gully C, Velazquez-Torres G, Fuentes-Mattei E, Yeung G, Qiao Y, Chou PC, Su CH, Hsieh YC, Hsu SL, Ohshiro K, Shaikenov T, Wang H, Yeung SC, Lee MH. CSN6 drives carcinogenesis by positively regulating Myc stability. Nat Commun 5:5384, 2014. e-Pub 2014. PMID: 25395170.
- Quintás-Cardama A, Post SM, Solis LM, Xiong S, Yang P, Chen N, Wistuba II, Killary AM, Lozano G. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol 234(1):108-19, 2014. e-Pub 2014. PMID: 24890125.
- Pant V, Xiong S, Jackson JG, Post SM, Abbas HA, Quintás-Cardama A, Hamir AN, Lozano G. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev 27(17):1857-67, 2013. e-Pub 2013. PMID: 23973961.
- Quintás-Cardama A, Qiu YH, Post SM, Zhang Y, Creighton CJ, Cortes J, Kornblau SM. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer 118(21):5283-92, 2012. e-Pub 2012. PMID: 22517119.
- Post SM. Mouse models of sarcomas: critical tools in our understanding of the pathobiology. Clin Sarcoma Res 2(1):20, 2012. e-Pub 2012. PMID: 23036318.
- Lee HJ, Zhang X, Attie Y, Post SM. Knowing is Half the Battle in the Genetics of Acute Myelogenous Leukemia. Genetic Syndromes & Gene Therapy 112(3), 2012.
- Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T, Lozano G. Multiple stress signals activate mutant p53 in vivo. Cancer Res 71(23):7168-75, 2011. e-Pub 2011. PMID: 21983037.
- Jackson JG, Post SM, Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol 223(2):127-36, 2011. e-Pub 2010. PMID: 20957626.
- Post SM, Lozano G. You can win by losing: p53 mutations in rhabdomyosarcoms. Journal of Pathology. Journal of Pathology 222(2):124-8, 2010.
- Post SM, Lozano G. You can win by losing: p53 mutations in rhabdomyosarcomas. J Pathol 222(2):124-8, 2010. PMID: 20821751.
- Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, Lozano G. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 18(3):220-230, 2010. PMID: 20832750.
- Xiong S, Pant V, Suh YA, Van Pelt C, Wang Y, Valentin-Vega Y, Post SM, Lozano G. Spontaneous tumorigenesis in mice overexpressing Mdm4. Cancer Research 70(18):7148-54, 2010.
- Xiong S, Pant V, Suh YA, Van Pelt CS, Wang Y, Valentin-Vega YA, Post SM, Lozano G. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res 70(18):7148-54, 2010. e-Pub 2010. PMID: 20736370.
- Post SM, Pant V, Abbas H, Quintás-Cardama A. Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma. Oncotarget 1(3):168-74, 2010. PMID: 21301048.
- Post SM , Quintás-Cardama A. Closing in on the pathogenesis of the 5q- syndrome. Expert Rev Anticancer Ther 10(5):655-8, 2010. PMID: 20469997.
- Fang S, Krahe R, Lozano G, Han Y, Chen W, Bachinski LL, Post SM, Wilson C, Strong LC, Amos CI. The effect of Mdm2 and p53 codon72 polymorphisms on cancer risk in p53 germline mutation carriers. PLoS One 5(5), 2010.
- Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM , Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One 5(5):e10813, 2010. e-Pub 2010. PMID: 20520810.
- Post SM, Quintás-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene 29(9):1260-9, 2010. e-Pub 2009. PMID: 19935700.
- Martinez LA, Goluszko E, Chen H-Z, Leone G, Post SM, Lozano G, Chen Z, Chauchereau A. E2F3a is a Mediator of DNA Damage Induced Apoptosis. Mol. Cell. Bio 30(2):524-36, 2010.
- Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22(10):1337-44, 2008. PMID: 18483220.
- Song W, Levin DS, Varkey J, Post SM, Bermudez VP, Hurwitz J, Tomkinson AE. A conserved physical and functional interaction between the cell cycle checkpoint clamp loader and DNA ligase I of eukaryotes. J. Biol. Chem 282(31):22721-30, 2007.
- Post SM, Groenendijk M, Solaas K, Rensen PC, Princen HM. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. Arterioscler Thromb Vasc Biol 24(4):768-74, 2004. e-Pub 2004. PMID: 14962946.
- Motycka TA, Bessho T, Post SM , Sung P, Tomkinson AE. Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52. J. Biol. Chem 279(14):13634-9, 2004.
- Post SM, Lee EY. Detection of kinase and phosphatase activities. Methods Mol Biol 241:285-97, 2004. PMID: 14970662.
- Post SM, Tomkinson AE, Lee EY. The human checkpoint Rad protein Rad17 is chromatin-associated throughout the cell cycle, localizes to DNA replication sites, and interacts with DNA polymerase epsilon. Nucleic Acids Res 31(19):5568-75, 2003. PMID: 14500819.
- Post SM, Weng YC, Cimprich K, Chen LB, Xu Y, Lee E. Phosphorylation of serines 635 and 645 of human Rad17 is cell cycle regulated and is required for G1/S checkpoint activation in response to DNA damage. Proc Natl Acad Science 98(23):13102-13107, 2001.
Invited Articles
- Aitken MJL, Lee HJ, Post SM. Emerging treatment options for patients with p53-pathway-deficient CLL. Ther Adv Hematol 10(2040620719891356):2040620719891356, 2019. e-Pub 2019. PMID: 31839919.
- Post SM. One size doesn't fit all in Ph-like ALL. Blood 12(129):140-141, 2017. PMID: 28082291.
Book Chapters
- Post SM, Kantarjian H, Quintas-Cardama A.. Biology of Adult Myelocytic Leukemia and Myelodysplasia. In: The Molecular Basis of Cancer. In: The Molecular Basis of Cancer (Fourth Edition), 421-432, 2014.
- Post SM, Quintas-Cardama A, Lozano G. Regulation of p53 Activity and Associated Checkpoint Controls. In: Checkpoint Controls and Targets in Cancer Therapy, Cancer Drug Discovery and Development. In: Springer Science, 171-188, 2010.
Patient Reviews
CV information above last modified July 15, 2024